Medigene is a publicly listed biotechnology company headquartered in Martinsried near Munich, Germany. Medigene concentrates on the development of personalized T cell immunotherapies with a focus on haematological malignancies. Medigene is the first German biotech company to have revenues from a marketed product, which is distributed by commercial partner companies. Medigene has advanced drug candidates which are licensed to partners and additional candidates in clinical development. The company is developing highly innovative treatment platforms concentrating on cancer and autoimmune diseases.
Quote | Medigene Ag Ord (OTCMKTS:MDGEF)
Last: | $2.43 |
---|---|
Change Percent: | 0.0% |
Open: | $2.43 |
Close: | $2.43 |
High: | $2.43 |
Low: | $2.43 |
Volume: | 500 |
Last Trade Date Time: | 03/28/2024 03:00:00 am |
News | Medigene Ag Ord (OTCMKTS:MDGEF)
2024-03-28 13:18:08 ET Medigene AG (MDGEF) Full Year 2023 Earnings Conference Call March 28, 2024 10:00 AM ET Company Participants Pamela Keck – Head-Investor Relations Selwyn Ho – Chief Executive Officer Conference Call Participants Sara Ni...
Significant corporate and scientific progress in 2023 Innovations to End-to-End Platform technologies and IP portfolio Pipeline additions with multiple KRAS neoantigen targets Advancement of lead program MDG1015 with IND/CTA approval expected in 2H 2024 Partnering expansion with n...
Message Board Posts | Medigene Ag Ord (OTCMKTS:MDGEF)
Subject | By | Source | When |
---|---|---|---|
dhovekamp42: Attention will come with this 1st commercial TCR immunotherapy deal of German Medigene | dhovekamp42 | investorshangout | 09/29/2016 8:02:37 AM |
News, Short Squeeze, Breakout and More Instantly...
Medigene Ag Ord Company Name:
MDGEF Stock Symbol:
OTCMKTS Market:
Significant corporate and scientific progress in 2023 Innovations to End-to-End Platform technologies and IP portfolio Pipeline additions with multiple KRAS neoantigen targets Advancement of lead program MDG1015 with IND/CTA approval expected in 2H 2024 Partnering expansion with n...
Planegg/Martinsried, March 19, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, will be participating in the H.C. Wainwright 2nd A...
Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, will report financial results and provide a corporate update for the fiscal year ended Dece...